The US Food and Drug Administration transition to its pre-COVID, in-person advisory committee meeting format is bringing a sudden surge in scheduled meetings.
Key Takeaways
-
The FDA’s move back to fully in-person advisory committee meetings coincided with a surge in scheduled sessions.
The 9 September review of Iterum Therapeutics plc's sulopenem will be a milestone event. The agency will be allowing...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?